🧠 When the brain progresses but the rest of the disease is controlled, do we really need to change everything?
@OncoAlert
At #ESMO26, phase II BRIDGET explores a very practical strategy in HER2+ metastatic #BreastCancer:
After SRS for isolated intracranial progression, add tucatinib while continuing the existing HER2-directed backbone.
📊 47 evaluable patients
➡️ Median intracranial PFS: not reached
➡️ 6-month iPFS: 91%
➡️ 12-month iPFS: 64%
➡️ 18-month iPFS: 59%
➡️ Grade ≥3 AEs: 15%
➡️ Extracranial progression: 4.3%
🎯 Why this matters: isolated CNS progression does not necessarily mean the entire systemic strategy has failed.
For me, this is a compelling example of site-specific treatment adaptation:
treat the resistant compartment locally, reinforce CNS control with tucatinib, and preserve an otherwise effective systemic regimen.
That may be one of the most clinically relevant forms of precision oncology.
Excellent work from @drsarahsam @DrVanSwearingen @rashmikmurthy @CareyAnders1 and the BRIDGET investigators.
Pinging @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @kevinpunie @GaiaGriguolo
#OncoAlert #ESMO26 #HER2 #BrainMetastases #Tucatinib #PrecisionOncology
151 浏览 · 2 赞 · 2 转发 · 0 回复
Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgOncoAlert 4Sight Abstracts to be Presented at #ESMO26 BRIDGET: A Phase II Trial of Tucatinib Added to Trastuzumab/Pertuzumab or Ado-Trastuzumab Emtansine After Isolated Intracranial Progression in Patients With Advanced HER2-Positive Breast Cancer @drsarahsam @DrVanSwearingen @rashmikmurthy @CareyAnders1 🔬 Single-arm phase II (47 evaluable): tucatinib added to ongoing HP or T-DM1 after SRS for isolated intracranial progression in HER2+ MBC. Primary endpoint: iPFS (RANO-BM). ➡️ Median iPFS not reached; p<0.0001 vs historical median of 5 mo ➡️ iPFS 91% at 6 mo, 64% at 12 mo, 59% at 18 mo ➡️ Grade ≥3 AEs 15%; extracranial progression 4.3% ✅ Adding tucatinib to HP after radiation met the primary endpoint, with more than half of patients free of intracranial progression at 18 months. #BreastCancer 🎙️ Sarah Sammons 👥 Amanda Van Swearingen · Laura Noteware · Nusayba Bagegni · Kelly Moulton · Stevie Threatt · Denise Jaggers · Shannon Shea · Eric Lipp · Erin Riley · Sin-Ho Jung · Gloria Broadwater · Masey Ross · Kimberly Strickland · Sasha Beyer · Alison Conlin · Aki Morikawa · Rashmi Murthy · Carey Anders (4Sight Made from Abstracts publicly available at the ESMO website) Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76在 X 查看被引用的帖子
来源：Dra. María Natalia Gandur Quiroga · x.com